RxDoctor Payments Data

Jenny Cascio

Psychiatric/Mental Health · Williamsville, NYNPI 1578727798

Payments from drug & device makers

$3,042in general payments, 2019–2025

Across 136 payments — averaging $22.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$423
  • AbbVie$382
  • Otsuka America Pharmaceutical, Inc.$330
  • Johnson & Johnson$272
  • Alkermes, Inc.$235
  • Axsome Therapeutics, Inc.$205
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,042100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,042 in reported general payments places this provider in the 85th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$9,622
Medicare patients
18
Services billed
118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Effexor XrVenlafaxine Hcl18$23,665
Lurasidone Hcl23$16,203
Nimodipine12$7,627
Duloxetine Hcl105$2,649
Fluoxetine Hcl50$2,142
Divalproex Sodium17$1,679
Bupropion XlBupropion Hcl69$1,674
Paroxetine CrParoxetine Hcl12$1,010
Clonazepam87$827
Alprazolam106$681
Oxcarbazepine16$680
Escitalopram Oxalate54$643
Sertraline Hcl38$584
Methylphenidate Hcl22$479
Venlafaxine Hcl22$474

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$63$58438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →